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Abstract Intravenously injected polystyrene nanoparticles,
which are prone to rapid sequestration by professional phago-
cytes, are converted to stealth entities by prior bolus intravenous
injection of poloxamine 908. This behaviour is not due to alter-
ation in macrophage phagocytic activity. Laser Doppler ane-
mometry and surface plasmon resonance were used to unravel
the mechanisms fundamental to generation of such stealth enti-
ties in vivo by poloxamine 908. Electrophoretic mobility of po-
loxamine pre-coated monodisperse polystyrene nanoparticles in
serum, which behave as stealth entities in vivo, was similar to
that of uncoated nanoparticles incubated in poloxamine pre-
treated serum. This observation supported the notion that polox-
amine in serum can modify the surface of nanoparticles with
similar topography to that of stealth poloxamine pre-coated
particles, i.e. with polyoxyethylene chains projected from the
surface. Surface plasmon resonance optical phenomenon was
used for real-time monitoring of protein^poloxamine interac-
tions and adsorption at the polystyrene interface. It was found
that poloxamine can not only adsorb to a serum-modi¢ed sur-
face but in addition poloxamine in serum can form macromo-
lecular complexes with high a⁄nity for adsorption to a polysty-
rene lattice. A role for serum albumin in surface modi¢cation of
nanoparticles by poloxamine 908 is also identi¢ed. Hence, our
biophysical observations correlate precisely with the in vivo lon-
gevity of uncoated polystyrene nanoparticles in poloxamine pre-
treated rats. This rational and sensitive biophysical approach
has unravelled the probable mechanism fundamental to genera-
tion of stealth entities in vivo and therefore has application in
the design and nano-engineering of stealth colloidal carriers for
optimal biological performance.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The biological performance of colloidal particles in vascu-
lature can be altered by surface modi¢cation with non-ionic
block copolymers such as poloxamer 407 and poloxamine 908
[1,2]. For instance, following intravenous injection into rats or
mice, polystyrene nanoparticles (sub-100 nm) that are pre-
coated with a su⁄cient surface density of either poloxamer
407 or poloxamine 908 escape rapid detection and clearance
by the body’s scavenger cells [3,4]. As a result, these surface-
modi¢ed nanoparticles exhibit prolonged circulation times
when compared to untreated particles. In contrast to this
classical approach, a recent study from this laboratory dem-
onstrated that the circulatory half life of intravenously in-
jected uncoated polystyrene nanoparticles, which are prone
to rapid phagocytosis, can equally be increased by prior intra-
venous injection of either poloxamine 908 or poloxamer 407
(140 mg/kg) to rats [5,6]. To date, the in vivo observations
support the notion that nanoparticles in the blood are sponta-
neously converted to long circulating entities by prior injec-
tion of such copolymers. The precise mechanism(s) of this
conversion remains unknown but is presumably linked to gen-
eration of a steric barrier by poloxamine 908 molecules to
combat phagocytic recognition. Interestingly, serum proteins
are known to rapidly coat the surface of nanoparticles ; a
process that leads to surface opsonisation. This raises the
question as to how such small quantities of copolymers in
competition with serum proteins can re-arrange the interfacial
surface dynamics to generate stealth entities under in vivo
shear forces.
The aim of this paper is therefore to understand the bio-
physical basis of nanoparticle surface modi¢cation by polox-
amine 908 in the presence of serum proteins. We have used
two complementary approaches to determine the nature of
such interactions. Firstly, the mobility of monodispersed poly-
styrene nanoparticles was measured in a de¢ned electric ¢eld
[7,8]. Thus, we compared the electrophoretic mobility of po-
loxamine-coated polystyrene nanoparticles both in the ab-
sence and in the presence of serum to that of uncoated poly-
styrene nanoparticles incubated in poloxamine pre-treated
serum. Therefore, a similar mobility pro¢le between the two
treatments would suggest that the poloxamine in serum can
coat the surface of nanoparticles with similar topography to
that of stealth poloxamine pre-coated particles (e.g. with poly-
oxyethylene chains projected from the particle surface). With
the aid of surface plasmon resonance (SPR) [9,10] we moni-
tored the real-time protein^poloxamine interactions and the
assembly of possible macromolecular complexes at the poly-
styrene interface, which may impart the stealth-like behaviour
observed in vivo. Our observations re£ect precisely the in vivo
longevity of uncoated model polystyrene nanoparticles in po-
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loxamine pre-treated rats. These approaches may be adopted
for surface engineering of biodegradable nanoparticles such as
poly(lactide-co-glycolide) (PLGA) nanospheres for optimal
therapeutic performance.
2. Materials and methods
2.1. Nanosphere treatments and electrophoretic mobility measurements
Monodispersed polystyrene nanospheres (2.5% w/v), 56L 4.9 nm in
diameter, manufactured by Polysciences (Warrington, PA, USA),
were purchased from Park Scienti¢c (Northampton, UK) and this
batch was used in all experiments. Poloxamine 908 was a gift from
BASF Corp. (Mt. Olive, NJ, USA) and was used as received. Poly-
styrene nanospheres (0.8 mg) were incubated with di¡erent concen-
trations of poloxamine 908 or physiological concentration of bovine
serum albumin (BSA), 40 mg/ml, or bovine IgG (10 mg/ml), in 10 mM
McIlvaine bu¡er, pH 7.2, for 1 h at room temperature in a total
volume of 1.0 ml. In some experiments, poloxamine (¢nal concentra-
tion in the range of 0.5^5.0 mg/ml) was incubated with foetal calf
serum (¢nal concentration 50% v/v) for 15 min at room temperature.
To this mixture, uncoated polystyrene nanospheres (0.8 mg) were
added. The total volume was adjusted to 1.0 ml with 10 mM Mc-
Ilvaine bu¡er and the pH was maintained between 7.0 and7.2 and the
suspension was incubated for a period of 15 min. The electrophoretic
mobility of all nanospheres was measured in 10 mM McIlvaine bu¡er,
pH 7.2, using a Zetasizer 3000 system (Malvern Instruments, UK) [7].
Furthermore, the electrophoretic mobility of poloxamine-coated
nanospheres was also evaluated in the presence of 50% v/v foetal
calf serum. All electrophoretic mobility measurements were deter-
mined at a dielectric constant of 78.3, current of 1.4 mA, £uid refrac-
tive index of 1.35, cell ¢eld of 29.3 V/cm, conductivity of 0.7 mS/cm
and viscosity of 0.89 cP [7]. In a further series of experiments, poly-
styrene nanospheres (0.8 mg) were incubated either in 50% v/v fresh
or heat-denatured (56‡C/30 min) foetal calf serum for 30 min at room
temperature to allow for serum protein adsorption. Following such
treatment, poloxamine 908 (5.0 mg) was added and the mixture was
incubated for a further period of 15 min at room temperature. The
total volume was kept to 1.0 ml and the pH was maintained in the
range of 7.0^7.2. Following all incubations, the electrophoretic mo-
bility of nanospheres was measured as described above.
2.2. Slide preparation, surface assessment and SPR studies
SPR experiments were performed using a prototype Kretchmann
con¢guration instrument (Johnson and Johnson Orthoclinical Diag-
nostics, Chalfont St. Giles, UK), as described in detail elsewhere [10].
Brie£y, SPR slides with silver dielectric layer (obtained from the same
source) were modi¢ed prior to use with a layer of polystyrene. Prior to
modi¢cation, the surfaces of the silver slides were analysed by atomic
force microscopy (AFM) using a Digital Instruments Nanoscope
(Digital Instruments, Cambridge, UK) in contact mode with silicon
nitride tips. Slides were optically matched to the instrument prism
using low-viscosity microscope immersion oil (Resolve, Stephens Sci-
enti¢c, Riverdale, NJ, USA). The analysis con¢rmed that the surfaces
were smooth for a 5 Wm scan. Polystyrene (280 000 Mw) was dissolved
in high-performance liquid chromatography (HPLC) grade toluene
(0.05% w/v) and spun-coated (2000 rpm) from a glass pipette
(3U250 Wl droplets) centrally, at a height of 5 mm above the spinning
slide. The presence of the polystyrene coating was con¢rmed by con-
tact angle measurements [11]. The sessile drop contact angle with 2 Wl
HPLC water droplet was 25.6L 1.2‡ and 89.5L 1.1‡ (n=6) for silver
SPR slides and polystyrene-coated SPR slides, respectively. Uniform-
ity and thickness of the applied layers was investigated with scanning
electron microscopy (SEM), on both £at surfaces and Z-axis-sectioned
slides, as well as AFM. For SEM, polystyrene-coated slides were
treated with palladium (2 nm) and visualised at 5 keV using a Joel
6310 scanning electron microscope (Joel, Welwyn Garden City, UK).
The polystyrene coating was continuous and the thickness was esti-
mated 95L 10 nm on Z-axis-sectioned slides. A minor degree of poly-
styrene surface roughness was detected by AFM for a 5 Wm scan.
Three £ow channels were described on the surface of the SPR slide,
with a thermally controlled head unit at 25L 0.1‡C. Liquid £ow across
the surface of the slides was achieved using a Shimadzu LC-9A dual
piston HPLC pump. The pump was connected in series with a Rheo-
dyne 9125 all-PEEK1 MBB six way injection valve and 20 Wl
PEEK1 loop, through which all samples were introduced to the
£ow stream. Flow rate for all experiments was ¢xed at 10 Wl/min.
The slide surfaces were treated ¢rst with bu¡er and subsequently
with either foetal calf serum (50% v/v) or heat-denatured (56‡C/30
min) calf serum (50% v/v) or poloxamine (5 mg/ml) or poloxamine-
treated calf serum (5 mg/ml poloxamine in 50% v/v serum). In some
experiments the surface of the SPR slide was treated ¢rst with serum
followed by immediate passage of poloxamine. Changes in the SPR
angle are expressed as millidegree angle change (mda) and were re-
corded at 2 s intervals using instrument speci¢c WinSPR V1.1 soft-
ware with initial data analysis carried out using similarly speci¢c
Wbplot software [10].
2.3. Viscosity measurements
The viscosity of foetal calf serum (50% v/v) and poloxamine (5 mg/
ml)-treated serum was measured at 25L 0.1‡C by Thermo Haake
RheoStress0 1 rheometer (Gebru«der HAAKE GmbH, Germany). A
C60 cone-plate sensor system with 1‡ angle and a gap of 0.054 mm
was used. Data analysis was carried out with the Thermo Haake
software RheoWin Pro.
2.4. Biodistribution studies
Polystyrene nanoparticles were surface-labelled with Na[125I] by a
radiation-induced bonding of iodine as described in detail previously
[12]. The labelled particles were cleaned by dialysis prior to surface
modi¢cation with copolymers and serum [12]. Male Wistar rats (body
weight, 150L10 g, meanL standard deviation) in groups of three were
injected intravenously via one of the lateral tail veins with either un-
coated or surface-modi¢ed [125I]-radiolabelled polystyrene nanopar-
ticles of 60 nm in diameter (0.8 mg polystyrene/150 g body weight).
In some experiments particles were pre-incubated in various media
(e.g. serum, BSA, IgG, serum and proteins pre-treated with polox-
amine 908) prior to intravenous injection. In all experiments the total
volume of injection was between 0.4 and 0.6 ml/animal. The circula-
tory activity of the nanoparticles was monitored by removal of the
blood (20 Wl) from the second tail vein at selected time intervals, and
animals were killed 3 h post-nanosphere administration for the anal-
ysis of the radioactivity present in key macrophage-rich organs (liver
and spleen). The whole liver and spleen were counted for radioactiv-
ity. To determine the amount of nanospheres in the blood, a total
blood volume per rat of 7.5 ml/100 g of the body weight was assumed
[3,5,6]. A correction factor for the blood content in the liver was
determined as described earlier [13]. The results are presented as a
percentage of the administered doseL standard error of mean for
each group.
Table 1
Electrophoretic mobility and body distribution of poloxamine-coated polystyrene nanoparticles
Poloxamine
(mg/ml)
Mobility
(1038 m2/V s)
Distribution at 3 h post-injection
(% of injected dose)
In bu¡er In serum Liver+spleen Blood
0 33.94L 0.19 32.66L 0.03 63.6L 2.0 1.0 L 0.1
0.5 30.99L 0.29 31.09L 0.02 20.6L 3.7 48.2L 1.9
1.0 30.82L 0.24 30.92L 0.06 9.3 L 1.6 63.4L 3.9
2.0 30.76L 0.13 30.88L 0.02 8.6 L 1.4 61.2L 2.2
5.0 30.73L 0.05 30.90L 0.03 9.9 L 1.2 58.6L 3.6
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3. Results and discussion
As shown in Table 1 the electrophoretic mobility of nano-
spheres is changed dramatically following poloxamine treat-
ment. The mobility values are similar, irrespective of the
initial poloxamine concentration. Since the equilibrium po-
loxamine concentration in all incubations is at the plateau
region of the adsorption isotherm, the polyoxyethylene chains
of the poloxamine are expected to be closely packed and
should exhibit a compressed ‘brush-like’ con¢guration that
extends from the particle surface [7]. This steric protection
by poloxamine 908 molecules explains the sharp drop in the
electrophoretic mobility values [7,8]. In the presence of 50%
v/v foetal calf serum the electrophoretic mobility values of
poloxamine-coated nanoparticles are slightly changed, which
could arise from some interaction between the adsorbed po-
loxamine molecules and serum proteins. This was also con-
¢rmed by SDS^PAGE (sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis ; data not shown) but the extent of
protein adsorption was considerably lower than that of un-
coated particles. This further supports the notion that the
surface-adsorbed poloxamine molecules provide some resis-
tance to protein adsorption and particle opsonisation [7,14].
Indeed, biodistribution studies also show that the sequestra-
tion of nanoparticles by scavengers of the reticuloendothelial
system is dramatically suppressed by prior poloxamine coat-
ing, and again this is irrespective of the initial poloxamine
concentration. As a result a large fraction of nanoparticles
remains within the vasculature at the time of killing. The
time of killing was chosen as 3 h for direct comparison with
previous studies [5,7] ; however, such surface-modi¢ed par-
ticles are known to circulate for longer periods of time [5].
In order to mimic the previous in vivo conditions [5], serum
was pre-treated with relevant concentrations of poloxamine
908 (similar to those encountered in the systemic circulation)
prior to nanoparticle addition. If poloxamine in serum can
coat the surface of nanoparticles in a similar manner to in-
cubations with no proteins, then close electrophoretic mobility
values are expected. The results in Table 2 demonstrate that
the incubation of uncoated nanoparticles with poloxamine-
treated serum can indeed modify their body distribution and
produce similar biodistribution as native poloxamine-coated
nanoparticles. The e¡ect is best seen with 2.0 mg poloxamine/
ml of serum, although at lower concentrations poloxamine
can still suppress particle retention in the liver and the spleen.
Remarkably, the electrophoretic mobility of nanoparticles in
poloxamine pre-treated serum (e.g. 2.0 and 5.0 mg polox-
amine/ml of serum) also resembles that of poloxamine pre-
coated nanoparticles in the serum. These observations further
con¢rm that even in the presence of serum proteins polox-
amine can equally modify the surface of nanoparticles. Pre-
viously, we [14] demonstrated that some unidenti¢ed serum
proteins act synergistically with the e¡ect of poloxamine coat-
ing to further suppress nanoparticle recognition by the liver
macrophages in vitro. Therefore, it is plausible that polox-
amine can form complexes with such proteins in serum with
high a⁄nity for the polystyrene surface. Such complexes may
even displace some of the adsorbed proteins from the poly-
styrene surface. Conversely, serum proteins, particularly albu-
Table 2
Electrophoretic mobility and body distribution of polystyrene nanoparticles following incubation in poloxamine-treated foetal calf serum
Poloxamine in serum
(mg/ml)
Mobility
(1038 m2/V s)
j potential
(mV)
Distribution at 3 h post-injection
(% of injected dose)
Liver+spleen Blood
0 32.66L 0.03 333.6L 0.4 66.8L 3.6 1.3L 0.8
0.5 31.26L 0.06 315.9L 0.8 33.3L 1.5 33.6L 1.8
1.0 31.11L 0.04 314.0L 0.5 27.7L 1.2 38.1L 2.3
2.0 30.88L 0.03 311.1L 0.4 10.2L 1.3 61.4L 3.7
5.0 30.81L 0.05 310.2L 0.7 9.1L 3.1 63.2L 5.2
(a)
1400
1800
2200
2600
3000
3400
3800
4200
66.5 67 67.5 68 68.5
SPR angle (degrees)
R
e
fl
e
c
ta
n
c
e
Initial angle
serum
Final angle
serum
(b)
1400
1800
2200
2600
3000
3400
3800
4200
66.5 67 67.5 68 68.5
SPR angle (degrees)
R
e
fl
e
c
ta
n
c
e
Initial angle 908
Final angle 908
(c)
 
2400
2800
3200
3600
4000
66.5 67 67.5 68 68.5
SPR angle (degrees)
R
e
fl
e
c
ta
n
c
e
Initial angle
908 in serum
Final angle
908 in serum
Fig. 1. The SPR curves from measurements of the re£ected intensity
as a function of angle. The curves are obtained following (a) injec-
tion of foetal calf serum (50% v/v), (b) poloxamine 908 (5 mg/ml)
and (c) poloxamine-treated foetal calf serum.
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min and IgG, are known to readily coat the surface of poly-
styrene nanospheres [7,15^18]. Hence, the mechanism of
poloxamine coating may simply arise from hydrophobic inter-
action between the polyoxypropylene segments of the po-
loxamine and surface-adsorbed proteins. Since albumin is
the most abundant protein in serum, its role in surface mod-
i¢cation of nanoparticles by poloxamine was investigated. The
results in Table 3 demonstrate a sharp drop in the electro-
phoretic mobility of BSA-coated nanoparticles following the
addition of poloxamine 908. Interestingly, this also results in
generation of nanoparticles with long circulating behaviour.
Furthermore, the mobility of nanoparticles is further reduced
when incubated in poloxamine-treated BSA. Again, the resul-
tant nanoparticles exhibit stealth behaviour when injected in-
travenously in a manner similar to that of poloxamine-treated
serum incubations. When BSA was replaced by bovine IgG
(10 mg/ml), poloxamine 908 failed to signi¢cantly alter the
electrophoretic mobility of nanoparticles; subsequently these
pre-treated nanoparticles were sequestered rapidly by the liver
and the spleen following intravenous injection (data not
shown). Therefore, a role for BSA^poloxamine complexes in
surface modi¢cation of nanoparticles seems probable.
In order to understand how poloxamine 908 in the presence
of serum proteins can modify a polystyrene surface SPR ex-
periments were performed. SPR is an evanescent wave tech-
nique, which allows the real-time monitoring of interactions
with surfaces [9]. The wave pro¢le is dependent on the thick-
ness and refractive index of the layer above the polystyrene
¢lm [19]. Changes in this layer require a new angle of incident
light to initiate resonance [19]. Therefore, change in the SPR
angle with time is measured using a photodiode detector,
along with the depth and shape of the ‘dip angle’. SPR results
are presented as time-resolved traces as well as in the form of
the re£ectivity versus angle curves [10,19]. Serum (50% v/v)
was found to adsorb strongly to a polystyrene SPR-coated
slide surface with a value of 635L 35 mda and an initial slope
of 0.48 mda/s. A second injection of serum had no further
e¡ect. The SPR re£ectance curve, as the initial and ¢nal scans
during the adsorption process, con¢rmed the presence of the
adsorbed layer of serum proteins on the polystyrene surface
(Fig. 1a). The signi¢cant shift in the baseline SPR angle from
67.25‡ to 67.9‡ with a concomitant £attening of the pro¢le
suggests the adsorption of a relatively thick layer of protein-
aceous material [19]. This experiment mimicked the condition
where polystyrene nanoparticles are in continuous contact
with serum. In the case of poloxamine 908 (Fig. 1b) the ad-
sorption pro¢le generated 0.5‡ shift in baseline angle with a
small decrease in re£ectivity, hence suggesting a presence of a
thin poloxamine layer on the sensor surface. Again, the addi-
tion of poloxamine to serum (Fig. 1c) resulted in a signi¢cant
shift in angle (0.3‡) with a concomitant £attening of the curve.
In both cases of poloxamine and poloxamine-treated serum,
the pre-existing small secondary minimas suggest some under-
lying inhomogeneous roughness on the polystyrene-coated
slide [19]. Interestingly, the adsorption pro¢les for poloxamine
and poloxamine-treated serum appeared similar and were
78L 3 and 97L 5 mda, respectively. The similarity of the val-
ues suggests that in the case of poloxamine-treated serum,
poloxamine and/or poloxamine^protein complexes are ad-
sorbed on to the polystyrene surface. However, the rate of
adsorption isV3 times higher with poloxamine-treated serum
when compared to the passage of serum and poloxamine
under identical £ow conditions (1.19 vs. 0.42 mda/s). The
rate of adsorption is known to be dependent on mass trans-
port and intrinsic kinetics [20,21]. However, the ¢nal concen-
trations of both serum and poloxamine were constant in all
systems, and furthermore there was no signi¢cant change in
serum viscosity following poloxamine addition. On the basis
of these observations the mass transport can not explain the
higher rate of adsorption seen following the passage of polox-
amine-treated serum. We therefore conclude that poloxamine
in serum can form macromolecular complexes and these pre-
sumably have higher a⁄nity for adsorption to a polystyrene
surface.
Previously, we also reported an intriguing observation in
the body distribution of intravenously injected polystyrene
nanospheres that were pre-coated ¢rst with either rat serum
or heat-denatured rat serum then followed by addition of
poloxamine [5]. The results in Table 3 also con¢rm these ob-
servations with foetal calf serum. Again, poloxamine is able to
exert some degree of protection to nanospheres that were pre-
coated with serum, but not with heated serum, against hepatic
sequestration. In addition, we also show that poloxamine can
coat the surface of serum pre-treated nanoparticles since there
is a dramatic drop in the electrophoretic mobility of nano-
spheres when compared to serum-coated nanoparticles. This
stealth property may arise simply by adsorption of polox-
amine to the surface-adsorbed proteins or as a result of pro-
tein displacement from the surface by poloxamine, or both.
Conversely, the electrophoretic mobility measurements con-
¢rm that poloxamine is unable to adsorb e⁄ciently on to
surface of particles that were pre-treated with heated serum.
Table 3
Electrophoretic mobility and body distribution of BSA- and serum-pre-treated polystyrene nanoparticles following poloxamine addition
Incubation protocol Mobility
(1038 m2/V s)
j Potential
(mV)
Distribution at 3 h post-injection
(% of injected dose)
Liver+spleen Blood
A BSA (40 mg/ml) 32.52L 0.11 331.8L 1.4 63.3L 1.2 0.8 L 0.2
B 908 (5 mg/ml) 30.76L 0.07 39.5L 1.5 8.9L 2.2 62.3L 4.8
C As (A) then poloxamine added (5 mg/ml) 31.05L 0.11 313.2L 1.4 20.3L 4.9 33.8L 5.8
D Poloxamine (5 mg/ml)-treated BSA (40 mg/ml) 30.46L 0.10 35.8L 1.3 9.7L 2.5 58.1L 2.3
E Heat-treated BSA (40 mg/ml) 31.97L 0.37 324.9L 4.6 60.1L 5.2 1.2 L 0.4
F As (E) then poloxamine added (5 mg/ml) 30.96L 0.07 312.2L 0.8 26.4L 3.9 33.2L 2.3
G Poloxamine (5 mg/ml)-treated heated BSA (40 mg/ml) 30.62L 0.23 37.9L 3.1 9.7L 3.1 67.2L 5.2
H Serum (50% v/v) 32.38L 0.11 330.2L 1.3 65.2L 3.6 2.3 L 1.7
I As (H) then poloxamine added (5 mg/ml) 31.44L 0.18 318.2L 2.2 28.7L 4.2 35.6L 3.4
J Heat-denatured serum (50% v/v) 32.43L 0.04 330.7L 0.5 59.7L 4.5 2.7 L 0.9
K As (J) then poloxamine added (5 mg/ml) 32.05L 0.07 325.9L 1.0 60.6L 2.9 1.8 L 0.6
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In order to con¢rm and determine the mode of poloxamine
adsorption on to a protein-coated surface, SPR studies were
conducted. To mimic the in vivo conditions, the polystyrene-
coated SPR slide was ¢rst enriched with serum proteins fol-
lowed by immediate passage of poloxamine and then serum
again. The SPR trace in Fig. 2 clearly indicates that polox-
amine 908 does not desorb serum proteins from the polysty-
rene surface. Interestingly, the poloxamine adsorbs to the pro-
tein-coated surface as evident from a further increase of 20L 2
mda and an initial slope of 0.06 mda/s. Furthermore, subse-
quent passage of serum induces a transient intermediate
change (an intermittent protein adsorption/desorption pro-
cess) but the ¢nal SPR angle value remains unchanged. These
observations may be indicative of the underlying ex vivo coat-
ing mechanisms and their inherent stability under in vivo
shear £ow and are in agreement with electrophoretic mobility
and biodistribution studies. From these observations we also
speculate the possibility of some surface re-arrangements with
poloxamine-pre-coated particles on contact with serum or
plasma. The validity of the SPR approach is further con¢rmed
with the passage of heat-denatured serum followed by polox-
amine washing. The SPR trace in Fig. 3 con¢rms modi¢cation
of the polystyrene surface with heat-denatured serum with a
¢nal change of 35L 4 mda. In contrast to serum, heat-dena-
tured serum seems to adsorb poorly on to the SPR slide.
However, subsequent passage of poloxamine shows very little
change in SPR angle shift and therefore is in agreement with
both the electrophoretic mobility and biodistribution studies.
These results indicate that the nature and conformation of
pre-adsorbed proteins on the surface of nanospheres can con-
trol subsequent interactions with poloxamine and/or polox-
amine^protein complexes. Due to the observed di¡erences be-
tween fresh and heat-denatured sera, one may consider a
regulatory role for surface-deposited complement and comple-
ment regulatory proteins in subsequent poloxamine binding.
On the basis of these observations we also evaluated the
role of serum albumin after heating at 56‡C/30 min on electro-
phoretic mobility and body distribution of polystyrene nano-
spheres in the presence of poloxamine 908. The results (Table
3) are strikingly similar to those of native albumin and further
support the involvement of other serum proteins in preventing
the adsorption of poloxamine on to the surface of nanopar-
ticles pre-treated with heat-denatured serum.
In conclusion, electrophoretic mobility measurements and
SPR studies have e¡ectively demonstrated plausible mecha-
nisms for surface modi¢cation of model polystyrene lattices
by poloxamine 908 in the presence of serum proteins. The
SPR approach can perhaps be translated to re-evaluate the
interaction between block copolymers and biodegradable
polymers used for nanosphere manufacturing (e.g. PLGA)
as well as model bilayers. Such investigations may lead to
novel approaches for surface engineering and development
of stealth biodegradable carriers as well as to understand
how block copolymers can span through biological mem-
branes [2,3,22].
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